Abstract
The major in vivo human metabolite of zatosetron is 8-alpha-methyl,8-beta-oxo zatosetron [N-O (1) zatosetron]. N-Desmethyl zatosetron (NdM zatosetron) and 3-hydroxy-zatosetron (3-OH-zatosetron) are minor human metabolites. In the rat, the primary in vivo metabolite is 3-OH-zatosetron. The enzyme kinetics of zatosetron metabolism were determined using human, rat, and monkey hepatic microsomal incubations. In the rat, the intrinsic clearance (IC; IC = Vmax/KM = microliter/min/mg of protein) of 3-OH-zatosetron (IC = 5.2) was favored over N-O (1) zatosetron (IC = 3.0) and NdM zatosetron (IC = 1.4). In the monkey, N-O (1) zatosetron exhibited the highest IC (IC = 7.0) relative to that for 3-OH-zatosetron (IC = 4.4) and NdM zatosetron (IC = 2.9). Monkey microsomes also formed 8-beta-methyl,8-alpha-oxo zatosetron (IC = 2.2). In two human samples (identified as HL-E and HL-J), the metabolic clearance of zatosetron favored the formation of N-O (1) zatosetron (HL-E, IC = 6.9; HL-J, IC = 2.9) over NdM zatosetron (HL-E, IC = 0.6; HL-J, IC = 0.3) and 3-OH-zatosetron (HL-E and HL-J, IC = 0.1). These results indicate that the monkey is better than the rat as a model for the exposure of humans to zatosetron and its metabolites.(ABSTRACT TRUNCATED AT 250 WORDS)
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|